ArticleFrontiers in oncology2025
Myth or reality: the oxygen effect in rectal cancer radiotherapy.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The oxygen microenvironment plays a crucial role in tumor radio-sensitivity, influencing the effectiveness of radiotherapy. The oxygen effect, which increases radiosensitivity in the presence of oxygen, has been extensively studied but not fully understood. This study investigates the relationship between hemoglobin variation, a surrogate marker for tissue oxygenation, and survival outcomes, in patients with locally advanced rectal cancer treated with neoadjuvant radiotherapy. Methods: In this retrospective study, we analyzed 97 patients with rectal adenocarcinoma treated with neoadjuvant pelvic radiotherapy between January 2016 and January 2024. Hemoglobin levels were measured before, during, and after radiotherapy, and hemoglobin variation (ΔHb) as a difference between maximum and minimum hemoglobin levels" was calculated. Active bone marrow (ABM) and low-density bone marrow (LDBM) were delineated for dosimetric analysis. Progression-free survival (PFS) was evaluated using Kaplan-Meier survival analysis, and the correlation between ΔHb, dosimetric data, and PFS was assessed using hazard ratios (HR) with a significance threshold of p < 0.05. Findings: The median volumes of LDBM and ABM were 114.6 cc and 765.4 cc, respectively. The maximal doses received by LDBM and ABM were 54.2 Gy and 52.2 Gy. The incidence of grade 3 and 4 anemia was 8.21%, with a mean delta hemoglobin (ΔHb) of 0.75%. No correlation was observed with grade 1-2 anemia at any dose level. A significant correlation was found between grade 3-4 anemia, ΔHb, and V40 doses for both LDBM and ABM (p-value < 0.05). Patients with ΔHb ≤ 1.5 demonstrated significantly better progression-free survival (PFS) compared to those with ΔHb > 1.5 (HR = 0.65, p = 0.0013). Dosimetric analysis revealed that higher doses to both ABM and LDBM regions did not correlate with improved PFS outcomes, while hemoglobin variation was a critical factor influencing survival. These results emphasize the role of hemoglobin variation and oxygenation in enhancing radio-sensitivity, particularly in active bone marrow. Interpretation: This study provides evidence that hemoglobin variation significantly influences survival outcomes in rectal cancer radiotherapy, supporting the clinical relevance of the oxygen effect. Hemoglobin monitoring and oxygenation strategies could be integrated into clinical practice to improve treatment efficacy, especially when considering dosimetric impacts on contoured bone marrow regions (ABM and LDBM). Future prospective studies are required to confirm these findings and explore interventions aimed at optimizing tissue oxygenation during radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.